Tislelizumab plus radiation for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have stage IIIB, IIIC, or IV non-squamous non-small cell lung cancer confirmed by biopsy.
- You have not had any previous chemotherapy or other systemic treatment for your lung cancer.
- You do not have an active autoimmune disease or a history of autoimmune reactions that are not under control.
- You do not have certain gene changes in your tumor (like EGFR, ALK, BRAF, ROS1, RET, or MET).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
This study tests a combination of three treatments—an immunotherapy drug called tislelizumab, chemotherapy, and a procedure called BACE—for advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and SYS6010, for people with advanced non-small cell lung cancer whose cancer has gotten worse after prior immunotherapy. It aims to see if this new combination can help when standard treatments have stopped working.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
This trial tests a combination of immunotherapy (tislelizumab) followed by surgery and radiation for people with a specific type of advanced lung cancer (N3 stage NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests if adding the immunotherapy drug Tislelizumab to standard chemotherapy can shrink stage III non-small cell lung cancer that cannot be surgically removed at first. The goal is to see if this combination makes the cancer small enough for surgery.
Hear when a new Tislelizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.